her2

News

Boehringer Ingelheim and Bayer logos with lung sketch in the middle

ESMO: Boehringer, Bayer seek first-line HER2+ NSCLC role

New trial data back the use of Boehringer's new oral HER2 inhibitor Hernexeos in front-line treatment of HER2+ NSCLC, but Bayer is in hot pursuit.

News

New data could move Enhertu into early breast cancer

AstraZeneca and Daiichi Sankyo's Enhertu has been shown to provide a benefit in a phase 3 trial in early-stage breast cancer for the first time.

News

Enhertu extends survival in advanced gastric cancer

Data from a phase 3 trial of Enhertu in advanced HER2-positive gastric cancer could support wider use as a second-line therapy.

News

Boehringer eyes third quarter FDA verdict for oral HER2 drug

Boehringer Ingelheim's oral HER2 inhibitor zongertinib has started an FDA review as a lung cancer treatment with a decision due in the third quarter.

News

Boost to Enhertu's prospects as FDA clears Roche diagnostic

Roche gets the first FDA approval for a diagnostic test for HER2-ultralow breast cancer, now on the label of AstraZeneca and Daiichi Sankyo's Enhertu.

News

Jazz gets first FDA nod for HER2 bispecific Ziihera

Jazz Pharma has claimed FDA approval for its HER2-directed bispecific antibody Ziihera as a treatment for biliary tract cancer

ESMO: Boehringer, Bayer seek first-line HER2+ NSCLC role

New data could move Enhertu into early breast cancer

Enhertu extends survival in advanced gastric cancer

Boehringer eyes third quarter FDA verdict for oral HER2 drug

Boost to Enhertu's prospects as FDA clears Roche diagnostic

Jazz gets first FDA nod for HER2 bispecific Ziihera

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

her2

Editor's Picks